Back to top
more

ChromaDex (CDXC)

(Delayed Data from NSDQ)

$3.44 USD

3.44
180,257

+0.05 (1.47%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 136.36% and 15.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 40% and 16.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 Weeks

by Zacks Equity Research

ChromaDex (CDXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks.com featured highlights Oxford Industries, ChromaDex, UserTesting and TravelCenters of America

by Zacks Equity Research

Oxford Industries, ChromaDex, UserTesting and TravelCenters of America have been highlighted in this Screen of The Week article.

Vaishali Doshi headshot

Bet on These 4 Top-Performing Liquid Stocks for Solid Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Oxford Industries (OXM), ChromaDex (CDXC), UserTesting (USER) and TravelCenters of America (TA), which investors can add to their portfolio for returns.

ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 27.27% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of -30.00% and 0.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.